Janssen, however, also marketed Risperdal as a treatment for older people with agitation from dementia, which is not an FDA-approved use of the medication. In fact, it can be dangerous for older adults with dementia to take antipsychotics, including Risperdal, and Janssen had to pay a fine for misbranding the drug.